Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus.
We are developing the promise of endoxifen and exploiting its potential to both help prevent as well as to treat breast cancer with our proprietary Topical and Oral Endoxifen.
We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.
We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.
